Myeloma Clinical Trials

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

$NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma$

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma Study of ORIC-533 in Relapsed or Refractory Multiple...

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...

NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)

NCT05338775: Phase 1: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor...

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding...

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721:...

$NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma$

NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...

NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function

DREAMM 12 Relapsed & Refractory Myeloma NCT04398745: Phase 1: A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma...